Published in Pathologe on May 01, 2010
Effects of the compounds resveratrol, rutin, quercetin, and quercetin nanoemulsion on oxaliplatin-induced hepatotoxicity and neurotoxicity in mice. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.81
Establishment of a standardized liver fibrosis model with different pathological stages in rats. Gastroenterol Res Pract (2012) 0.80
Age- and Gender Dependent Liver Fat Content in a Healthy Normal BMI Population as Quantified by Fat-Water Separating DIXON MR Imaging. PLoS One (2015) 0.78
[Update of the S3 guidelines for pancreatic cancer. What is new for pathologists?]. Pathologe (2014) 0.77
Phosphatase and tensin homolog is a differential diagnostic marker between nonalcoholic and alcoholic fatty liver disease. World J Gastroenterol (2016) 0.76
[Chronic liver diseases--new therapy. Are biopsies necessary?]. Pathologe (2013) 0.75
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol (1999) 14.07
Steatohepatitis: a tale of two "hits"? Gastroenterology (1998) 13.21
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology (1999) 11.76
Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology (2006) 9.34
Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology (2003) 8.75
Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc (1980) 8.36
Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology (2005) 7.03
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology (2007) 6.68
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol (2006) 5.78
Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology (1994) 5.22
Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology (2008) 5.07
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology (2006) 4.60
Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis (2001) 4.44
NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology (2002) 4.44
Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol (2008) 4.21
Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology (2005) 4.21
Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology (1999) 3.99
The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology (1995) 3.73
Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology (2007) 3.58
Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg (2006) 3.05
The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol (2003) 3.04
Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol (2006) 2.71
Sources of variability in histological scoring of chronic viral hepatitis. Hepatology (2005) 2.64
Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis (2001) 2.56
Non-alcoholic fatty liver disease. J Gastroenterol Hepatol (2002) 2.32
A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg (2008) 2.20
Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis (2002) 2.17
Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol (2002) 2.16
Nonalcoholic steatohepatitis. Gastroenterology (2001) 2.12
Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr (2000) 2.11
Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg (2008) 2.10
Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol (2003) 2.01
Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr (2007) 1.99
Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology (2006) 1.98
Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology (2006) 1.90
Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J Hepatol (2008) 1.68
Non-alcoholic fatty liver disease: current concepts and management strategies. Clin Med (2006) 1.65
American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology (2002) 1.63
Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol (2007) 1.59
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer (2007) 1.58
Non-alcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol (2005) 1.54
Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately? J Hepatol (2008) 1.53
The epidemiology of fatty liver. Eur J Gastroenterol Hepatol (2004) 1.44
Update on non-alcoholic fatty liver disease in children. Clin Nutr (2007) 1.43
Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care (2004) 1.42
Diagnosis and interpretation of steatosis and steatohepatitis. Semin Diagn Pathol (1998) 1.39
Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum Pathol (2004) 1.35
Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis (2007) 1.33
Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol (2004) 1.32
Pathology of nonalcoholic steatohepatitis. Hepatol Res (2005) 1.28
Definitive diagnosis and assessment of risk for nonalcoholic fatty liver disease in children and adolescents. Semin Liver Dis (2007) 1.24
Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int (2007) 1.24
Pathology of fatty liver disease. Mod Pathol (2007) 1.19
Review: nonalcoholic steatohepatitis. J Gastroenterol Hepatol (1997) 1.14
Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod Pathol (2003) 1.12
Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) (2006) 1.09
Diagnostic evaluation of nonalcoholic fatty liver disease. J Clin Gastroenterol (2006) 1.07
Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Semin Diagn Pathol (2005) 1.06
Pathological features of NASH. Front Biosci (2005) 1.05
When is steatosis too much for transplantation? J Hepatol (2006) 1.04
Alcoholic and nonalcoholic steatohepatitis. Clin Liver Dis (2002) 0.98
Non-alcoholic steatohepatitis in children. Clin Liver Dis (2007) 0.96
Proposal for a histological scoring and grading system for non-alcoholic fatty liver disease. Liver Int (2005) 0.95
Relationship between aminotransferase levels and histopathological findings in patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2000) 0.94
Approaches to liver biopsy techniques--revisited. Semin Liver Dis (2006) 0.91
Pathology of steatohepatitis. Best Pract Res Clin Gastroenterol (2002) 0.89
[Prevalence of overweight and adiposity in German school children]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2007) 0.88
[Chemotherapy associated hepatotoxicity in the treatment of advanced colorectal cancer (CRC)]. Z Gastroenterol (2008) 0.85
Evolving pathophysiologic concepts in nonalcoholic steatohepatitis. Curr Gastroenterol Rep (2002) 0.83
Nonalcoholic fatty liver disease. Pediatr Ann (2006) 0.81
Analysis of liver allograft rejection related genes using cDNA-microarrays in liver allograft specimen. Transplant Proc (2001) 0.80
Steatohepatitis in children. Best Pract Res Clin Gastroenterol (2002) 0.80
Role of liver biopsy in the assessment of non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol (2004) 0.79
Chemotherapy-induced steatohepatitis in colorectal cancer patients. J Clin Oncol (2006) 0.77
[Alcoholic and non-alcoholic steatohepatitis]. Ther Umsch (2004) 0.75
Histological grading and staging of chronic hepatitis. J Hepatol (1995) 19.57
Non-A, non-B hepatitis in chimpanzees and marmosets. J Infect Dis (1981) 4.15
Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. Aliment Pharmacol Ther (2013) 3.59
Wilson's disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology (1997) 3.52
Diversity of cytokeratins. Differentiation specific expression of cytokeratin polypeptides in epithelial cells and tissues. J Mol Biol (1981) 3.37
Expression of an ASCL2 related stem cell signature and IGF2 in colorectal cancer liver metastases with 11p15.5 gain. Gut (2010) 3.24
KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch (2008) 2.78
Prevalence of flat lesions in a large screening population and their role in colonoscopy quality improvement. Endoscopy (2013) 2.72
Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene (2006) 2.49
Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40. J Clin Pathol (2006) 2.33
Differentiation-related patterns of expression of proteins of intermediate-size filaments in tissues and cultured cells. Cold Spring Harb Symp Quant Biol (1982) 2.32
Perforation of the esophagus after dilation treatment for dysphagia in a patient with eosinophilic esophagitis. Endoscopy (2006) 2.24
Biochemical and immunological identification of cytokeratin proteins present in hepatocytes of mammalian liver tissue. Exp Cell Res (1981) 2.22
Splenectomy in proximal gastric cancer: frequency of lymph node metastasis to the splenic hilus. J Surg Oncol (2001) 2.20
Atypical ductular proliferation and its inhibition by transforming growth factor beta1 in the 3,5-diethoxycarbonyl-1,4-dihydrocollidine mouse model for chronic alcoholic liver disease. Lab Invest (1999) 2.16
Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood (1994) 2.16
Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis. Aliment Pharmacol Ther (2014) 2.15
Von Willebrand Factor as a new marker for non-invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C. Aliment Pharmacol Ther (2013) 2.12
Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology (2001) 1.92
Assembly of the major and the minor capsid protein of human papillomavirus type 33 into virus-like particles and tubular structures in insect cells. Virology (1994) 1.89
Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer (2001) 1.85
Expression of the gene of the alpha-smooth muscle-actin isoform in rat liver and in rat fat-storing (ITO) cells. Virchows Arch B Cell Pathol Incl Mol Pathol (1990) 1.83
Detection of hepatitis C virus in paraffin-embedded liver biopsies of patients negative for viral RNA in serum. Hepatology (1999) 1.79
[Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. Z Gastroenterol (2010) 1.76
Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer (1996) 1.76
Carcinoembryonic antigen (CEA) in gastrointestinal and extragastrointestinal tumors and its relationship to tumor-cell differentiation. Int J Cancer (1972) 1.75
Binding and internalization of human papillomavirus type 33 virus-like particles by eukaryotic cells. J Virol (1995) 1.70
TGF-beta1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol (1999) 1.69
Uptake of microparticle-adsorbed protein antigen by bone marrow-derived dendritic cells results in up-regulation of interleukin-1 alpha and interleukin-12 p40/p35 and triggers prolonged, efficient antigen presentation. Eur J Immunol (1995) 1.68
Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade--results of an explorative CGH meta-analysis. Br J Cancer (2005) 1.64
Detection of the His1069Gln mutation in Wilson disease by rapid polymerase chain reaction. Ann Intern Med (1997) 1.64
Modulation of alpha smooth muscle actin and desmin expression in perisinusoidal cells of normal and diseased human livers. Am J Pathol (1991) 1.62
Proinflammatory cytokines cause FAT10 upregulation in cancers of liver and colon. Oncogene (2008) 1.59
VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res (2000) 1.58
Experimental autoimmune hepatitis: disease induction, time course and T-cell reactivity. Hepatology (1990) 1.57
Neither intestinal sequestration of bile acids nor common bile duct ligation modulate the expression and function of the rat ileal bile acid transporter. Hepatology (1998) 1.56
Mediastinal angiomyolipomas in a male patient affected by tuberous sclerosis. Eur Respir J (2008) 1.55
[Regression of oesophageal carcinomas after neoadjuvant radiochemotherapy: criteria of the histopathological evaluation]. Pathologe (2004) 1.53
European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis (2013) 1.53
Evaluation of carbohydrate-deficient transferrin for detection of alcohol abuse in patients with liver dysfunction. Alcohol Alcohol (1995) 1.51
Differences of expression of cytoskeletal proteins in cultured rat hepatocytes and hepatoma cells. Exp Cell Res (1981) 1.51
Occurrence and immunolocalization of plectin in tissues. J Cell Biol (1983) 1.47
Immunocytochemical identification of epithelium-derived human tumors with antibodies to desmosomal plaque proteins. Proc Natl Acad Sci U S A (1983) 1.44
Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development. Oncogene (1998) 1.43
[Participation and support of clinical studies and other scientific investigations. Statement of the German Society for Pathology]. Pathologe (2013) 1.42
p21/waf1/cip1 in gastric cancer: associations with histopathological subtypes, lymphonodal metastasis, prognosis and p53 status. Scand J Gastroenterol (2001) 1.42
Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J Pathol (2006) 1.41
[Remove polyps and discard. Way or wrong way?]. Pathologe (2015) 1.39
Quantitative perfusion parameters of focal nodular hyperplasia and normal liver parenchyma as determined by electron beam tomography. Br J Radiol (1995) 1.38
Ultrastructural, biochemical, and immunologic characterization of Mallory bodies in livers of griseofulvin-treated mice. Fimbriated rods of filaments containing prekeratin-like polypeptides. Lab Invest (1979) 1.36
Woodchuck hepatitis virus X protein is present in chronically infected woodchuck liver and woodchuck hepatocellular carcinomas which are permissive for viral replication. J Virol (1996) 1.35
Formation and involution of Mallory bodies ("alcoholic hyalin") in murine and human liver revealed by immunofluorescence microscopy with antibodies to prekeratin. Proc Natl Acad Sci U S A (1979) 1.33
Hepatocellular expression of a dominant-negative mutant TGF-beta type II receptor accelerates chemically induced hepatocarcinogenesis. Oncogene (2001) 1.33
Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology (2001) 1.32
Hepatocyte growth factor/hepatopoietin A is expressed in fat-storing cells from rat liver but not myofibroblast-like cells derived from fat-storing cells. Hepatology (1992) 1.27
Biochemical and immunocytochemical analysis of the intermediate filament cytoskeleton in human hepatocellular carcinomas and in hepatic neoplastic nodules of mice. Lab Invest (1982) 1.27
Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology (1999) 1.25
[Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline]. Z Gastroenterol (2011) 1.24
Minilaparoscopy in the diagnosis of cirrhosis: superiority in patients with Child-Pugh A and macronodular disease. Endoscopy (2003) 1.24
Hepatocellular hyalin in cholestasis and cirrhosis: its diagnostic significance. Gastroenterology (1973) 1.23
Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J Viral Hepat (2001) 1.23
Staging of gastric cancer: correlation of lymph node size and metastatic infiltration. AJR Am J Roentgenol (1999) 1.23
A 10-year experience with Japanese-type radical lymph node dissection for gastric cancer outside of Japan. Cancer (1995) 1.22
Pronase pretreatment of tissue sections enhances sensitivity of the unlabelled antibody-enzyme (PAP) technique. J Immunol Methods (1977) 1.22
Expression and functional interaction of hepatocyte growth factor-scatter factor and its receptor c-met in mammalian brain. J Cell Biol (1994) 1.21
Cytokeratin 8 protects from hepatotoxicity, and its ratio to cytokeratin 18 determines the ability of hepatocytes to form Mallory bodies. Am J Pathol (2000) 1.21
Keratinocyte-derived granulocyte-macrophage colony stimulating factor accelerates wound healing: Stimulation of keratinocyte proliferation, granulation tissue formation, and vascularization. J Invest Dermatol (2001) 1.17
Mallory-Denk-bodies: lessons from keratin-containing hepatic inclusion bodies. Biochim Biophys Acta (2008) 1.17
Fat storing cells (FSC) of rat liver synthesize and secrete fibronectin. Comparison with hepatocytes. J Hepatol (1987) 1.17
Proteins of intermediate filaments. An immunohistochemical and biochemical approach to the classification of soft tissue tumors. Am J Pathol (1983) 1.16
Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse. Br J Cancer (2009) 1.16
Prognostic impact of p21/waf1/cip1 in colorectal cancer. Int J Cancer (2000) 1.16
Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J Hepatol (1996) 1.16
Prognostic relevance of tumour-associated macrophages and von Willebrand factor-positive microvessels in colorectal cancer. Virchows Arch (2004) 1.16
Lymph node size and metastatic infiltration in colon cancer. Ann Surg Oncol (1999) 1.15
Glutaric aciduria type I: pathomechanisms of neurodegeneration. J Inherit Metab Dis (1999) 1.14
Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology (2001) 1.14
SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway. J Pathol (2008) 1.14
Hepatocyte cytokeratins are hyperphosphorylated at multiple sites in human alcoholic hepatitis and in a mallory body mouse model. Am J Pathol (2000) 1.14
Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice. J Exp Med (1997) 1.13
Histologic observations in human hepatitis non-A, non-B. Hepatology (1982) 1.13
Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): a mechanism for methotrexate-mediated immunosuppression. Clin Exp Immunol (1999) 1.13
Role of sinusoidal endothelial cells of the liver in concanavalin A-induced hepatic injury in mice. Hepatology (1996) 1.12
Keratin-like proteins in normal and neoplastic cells of human and rat mammary gland as revealed by immunofluorescence microscopy. Differentiation (1981) 1.10
Phenotypical analysis and cytokine release of liver-infiltrating and peripheral blood T lymphocytes from patients with chronic hepatitis of different etiology. Liver (1994) 1.10
Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. Gastroenterology (2000) 1.10
The Genome Austria Tissue Bank (GATiB). Pathobiology (2007) 1.09
Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewis(a) and sialyl-Lewis(x) antigens in colorectal adenocarcinoma. Histopathology (2002) 1.08
Hepatocyte growth factor-stimulated invasiveness of monocytes. Blood (2000) 1.08